Premium
Successful allogeneic hemopoietic stem cell transplantation in a case of Wiskott–Aldrich syndrome and non‐Hodgkin lymphoma
Author(s) -
Tavil Betul,
Erdem Arzu Yazal,
Azik Fatih,
Isik Pamir,
Metin Ayse,
Emir Suna,
Uckan Duygu,
Tunc Bahattin
Publication year - 2013
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.12114
Subject(s) - medicine , stem cell , transplantation , fludarabine , busulfan , lymphoma , wiskott–aldrich syndrome , hematopoietic stem cell transplantation , immunology , haematopoiesis , human leukocyte antigen , cyclophosphamide , gastroenterology , chemotherapy , antigen , biochemistry , genetics , gene , biology , chemistry
WAS is a severe X‐linked recessive disorder characterized by microthrombocytopenia, eczema, and immunodeficiency. A six‐yr‐old boy with WAS diagnosed as B‐cell NHL (Stage III ) localized in the liver who underwent successful HSCT from HLA ‐one antigen mismatch sibling donor has been presented here. His conditioning regimen included ATG , busulfan, and fludarabine. He received 2.3 × 10 6 /kg CD 34(+) stem cells and 11 × 10 8 /kg nucleated cells at day 0. Neutrophil engraftment was achieved at day +14 and platelet engraftment at day +20. He has been in CR for more than two yr after transplantation. Thus, HSCT is an effective treatment for children with WAS even after development of lymphoma.